Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). (#364)
Makoto Tahara
1
,
Martin Schlumberger
2
,
Rossella Elisei
3
,
Mouhammed Amir Habra
4
,
Naomi Kiyota
5
,
Corina Dutcus
6
,
Jianbo Xu
7
,
Junming Zhu
7
,
Taro Hihara
8
,
Shannon McGrath
9
,
Mark Matijevic
9
,
Tadashi Kadowaki
8
,
Yasuhiro Funahashi
9
,
Brett Hughes
10
,
Steven Sherman
4
- Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
- Department of Nuclear Medicine and Endocrine Oncology, Centre de Reference Tumeurs Refractaires de la Thyroide, Gustave Roussy and University Paris-Sud, Villejuif, France
- Dipartimento Di Medicina Clinica e Sperimentale, Universita di Pisa, Pisa, Italy
- Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas, MD Anderson Cancer Centre, Houston, Texas, USA
- Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
- Oncology Product Creation Unit, Eisai Inc, Woodcliff Lake, NJ, USA
- Eisai Inc, Woodcliff Lake, NJ, USA
- Eisai Co., Ltd, Tokyo, Japan
- Eisai Inc., Andover, Maine, USA
- Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia